Drug Name Tegretol

Bioavailability is defined as the fraction of a given drug dose that reaches the circulation in unchanged form and becomes available for systemic distribution. The larger the presystemic elimination, the smaller is the bioavailability of an orally administered drug. Drugs are designed to exert a selective influence on vital processes in order to alleviate or eliminate symptoms of disease.
Binding to plasma protein is equivalent to a depot in prolonging the duration of the effect by retarding elimination, whereas the intensity of the effect is reduced. If two substances have affinity for the same binding site on the albumin molecule, they may compete for that site.

 

Adverse Effects of Antiplatelet Drugs All antiplatelet drugs increase the risk of bleeding. Even at the low ASA doses used to inhibit platelet function (100 mg/d), ulcerogenic and bronchoconstrictor (aspirin asthma) effects may occur. Ticlopidine frequently causes diarrhea and, more rarely, leukopenia, necessitating cessation of treatment.
Etomidate hardly affects the autonomic nervous system. Since it inhibits cortisol synthesis, it can be used in the treatment of adrenocortical overactivity (Cushing’s disease). Midazolam is a rapidly metabolized benzodiazepine (p. 228) that is used for induction of anesthesia.